Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$3.62
-3.5%
$5.32
$3.39
$16.00
$39.20M0.8754,023 shs62,597 shs
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
$0.14
-0.4%
$0.14
$0.15
$7.90
$611K1.1269,927 shs1,496 shs
Kineta, Inc. stock logo
KA
Kineta
$0.66
$0.33
$5.39
$7.04M0.46409,478 shs530,700 shs
Synlogic, Inc. stock logo
SYBX
Synlogic
$1.12
-0.9%
$1.13
$0.90
$1.88
$13.10M0.5618,285 shs12,465 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
0.00%-6.25%-21.55%-48.13%-71.37%
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
0.00%0.00%+3.85%-20.59%-97.73%
Kineta, Inc. stock logo
KA
Kineta
0.00%0.00%0.00%0.00%+24.56%
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00%+2.73%-0.88%-18.12%-29.38%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
4.0918 of 5 stars
4.45.00.00.03.31.71.3
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
1.7884 of 5 stars
3.50.00.00.00.62.50.6
Kineta, Inc. stock logo
KA
Kineta
N/AN/AN/AN/AN/AN/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
0.5954 of 5 stars
0.03.00.00.00.01.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
2.83
Moderate Buy$33.00811.60% Upside
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
3.00
Buy$23.0016,937.04% Upside
Kineta, Inc. stock logo
KA
Kineta
0.00
N/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SYBX, AVTX, KA, and BIOR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/25/2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageUnderperform ➝ Buy$23.00
3/25/2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$36.00
3/20/2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/20/2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$18.00
2/28/2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$48.00
(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$441K88.88N/AN/A$9.11 per share0.40
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
$892K0.68N/AN/A($36.43) per share0.00
Kineta, Inc. stock logo
KA
Kineta
$5.44M0.00N/AN/A$0.29 per share0.00
Synlogic, Inc. stock logo
SYBX
Synlogic
$8K1,637.44N/AN/A$4.64 per share0.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-$31.54MN/A0.00N/AN/AN/A-442.16%122.99%8/11/2025 (Estimated)
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
-$124.11M-$13.04N/AN/AN/AN/AN/A-332.47%5/27/2025 (Estimated)
Kineta, Inc. stock logo
KA
Kineta
-$14.10M-$1.50N/AN/AN/AN/A-1,044.95%-336.46%N/A
Synlogic, Inc. stock logo
SYBX
Synlogic
-$57.28M-$2.51N/AN/AN/AN/A-207.84%-114.81%5/27/2025 (Estimated)

Latest SYBX, AVTX, KA, and BIOR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/27/2025Q1 2025
Synlogic, Inc. stock logo
SYBX
Synlogic
-$0.15$0.0256+$0.1756N/AN/AN/A
5/12/2025Q1 2025
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-$1.07-$1.25-$0.18-$1.25N/AN/A
3/6/2025Q4 2024
Synlogic, Inc. stock logo
SYBX
Synlogic
-$0.10-$0.06+$0.04-$0.06N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
N/AN/AN/AN/AN/A
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
N/AN/AN/AN/AN/A
Kineta, Inc. stock logo
KA
Kineta
N/AN/AN/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
N/A
1.42
1.42
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
N/A
0.05
0.05
Kineta, Inc. stock logo
KA
Kineta
0.05
0.14
0.14
Synlogic, Inc. stock logo
SYBX
Synlogic
N/A
2.71
2.71

Institutional Ownership

CompanyInstitutional Ownership
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
87.06%
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
43.74%
Kineta, Inc. stock logo
KA
Kineta
30.32%
Synlogic, Inc. stock logo
SYBX
Synlogic
63.40%

Insider Ownership

CompanyInsider Ownership
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
3.03%
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
51.08%
Kineta, Inc. stock logo
KA
Kineta
23.70%
Synlogic, Inc. stock logo
SYBX
Synlogic
3.02%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
4010.83 million10.37 millionNot Optionable
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
1204.52 million2.21 millionOptionable
Kineta, Inc. stock logo
KA
Kineta
4012.25 million9.35 millionNot Optionable
Synlogic, Inc. stock logo
SYBX
Synlogic
8011.70 million11.34 millionOptionable

Recent News About These Companies

Synlogic Reports Q3 2024 Financial Outcomes
Synlogic Reports Third Quarter 2024 Financial Results
Synlogic, Inc. (0A8U.L)
MIN.SG,0P0001I7V6,0 (MIN.SG)
SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024
Synlogic Reports Second Quarter 2024 Financial Results
Synlogic Inc.
Synlogic Inc SYBX
Synlogic Flat on Q1 Numbers

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Avalo Therapeutics stock logo

Avalo Therapeutics NASDAQ:AVTX

$3.62 -0.13 (-3.47%)
Closing price 04:00 PM Eastern
Extended Trading
$3.79 +0.17 (+4.70%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Biora Therapeutics stock logo

Biora Therapeutics NASDAQ:BIOR

$0.14 0.00 (-0.37%)
As of 05/23/2025

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Kineta stock logo

Kineta NASDAQ:KA

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.

Synlogic stock logo

Synlogic NASDAQ:SYBX

$1.12 -0.01 (-0.88%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.